HCV Treatment Initiation During Acute Psychiatric Admission
INSPIRE: Interventions for Screening and Treatment of Psychiatric Inpatients With HCV Resulting in Elimination
Hepatitis C virus (HCV) disproportionally affects certain populations, including those facing substance use and mental health challenges. In the past, many individuals with mental illness were not treated due to the psychiatric side-effects of interferon. However, the development of highly effective, direct-acting antivirals (DAA) has revolutionized HCV treatment such that cure rates are >95% with 8-12 weeks of simple, safe, and well-tolerated therapy.
A recent systematic review reported that across 13 North American studies, HCV prevalence among people admitted to psychiatric hospitals was a staggering 17.4% (13.2-22.6%). Despite these concerning figures, mental health facilities have not been a focus of HCV elimination efforts to date. The Centre for Addiction and Mental Health (CAMH) in Toronto is the largest mental health facility in Canada, with a psychiatric emergency department seeing ~35 patients per day with many admitted to the acute psychiatric units for safety and stabilization. Currently, psychiatric patients screened for HCV at CAMH have a 75% 'no show' rate at the Toronto Centre for Liver Disease (TCLD), which is located less than 5km away, suggesting that referral upon discharge is ineffective.
This study will be the first trial to evaluate whether it would be feasible and beneficial to initiate treatment during an acute psychiatric admission rather than referring to specialty upon discharge. The combination of broad HCV screening with rapid linkage to treatment has led to successful elimination of HCV within defined populations, so-called micro-elimination. The investigators hypothesize that HCV treatment can be effectively delivered by providers in psychiatric care facilities, which will improve treatment uptake over traditional referral models.
연구 개요
연구 유형
등록 (예상)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Mia Biondi, NP-PHC, PhD
- 전화번호: 6476286461
- 이메일: mia.biondi@mail.mcgill.ca
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M6J 1H3
- 모병
- Centre for Addiction and Mental Health
-
연락하다:
- Renee Logan, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Chronic HCV infection, positive HCV RNA
- Aged 18 to 80
- Willingness and capacity to provide informed consent, or consent is provided by a substitute decision maker
Exclusion Criteria:
- Presence of or history of decompensated cirrhosis (evidence of decompensation with history of either ascites, variceal hemorrhage, or hepatic encephalopathy)
- Platelets < 75,000/mm3, total albumin <35 g/L, total bilirubin >34 μmol/L, INR >1.5
- History of current or past hepatocellular carcinoma.
- HBV (HBsAg +ve) co-infection or untreated HIV co-infection
- Prior HCV antiviral therapy with DAA with or without peginterferon/ribavirin
- Chronic liver disease other than mild nonalcoholic or alcoholic fatty liver disease from a cause other than HCV
- Pregnancy/breastfeeding/inability to use contraception
- Use of concomitant contraindicated medications
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Referral to outpatient specialty for HCV care
Acute psychiatric patients who test HCV RNA positive by OraQuick HCV Antibody Test will be referred for outpatient specialty follow-up at the Toronto Centre for Liver Disease (TCLD) where they will be assessed and offered treatment as per standard of care.
TCLD referrals are triaged by clinicians unaware of the trial and prioritized based on urgency of treatment.
Patients who do not attend the initial visit will be rescheduled.
After 3 'no-show' visits, the person will not be scheduled again at TCLD and will be deemed a 'treatment failure' for the trial with subsequent HCV follow-up at the discretion of the CAMH provider, consistent with current practice.
|
|
|
실험적: Receive HCV care during inpatient admission by a hospitalist
CAMH hospitalists covering the inpatient units will undergo a training designed for non-specialist providers, used in the ASCEND trial, which has already occurred.
An algorithm-based work-up which has been used for non-specialist treaters in ECHO Liver, a Ministry-of-Health supported tele-mentoring program, will then be completed for all who test HCV RNA positive.
Labs will be drawn by the hospital phlebotomist following a positive HCV RNA result from the Gene Xpert Viral Load Assay.
At this time, a sample will also be obtained to send to for conventional HCV RNA quantification and genotyping.
|
HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
SVR12 by intention to treat (ITT) in each arm
기간: 24 months
|
To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by intention to treat (ITT).
|
24 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
SVR12 by modified intention to treat (mITT) in each arm
기간: 24 months
|
To determine whether screening for HCV using rapid diagnostics during an acute psychiatric admission with inpatient initiation of HCV treatment is superior to standard post-discharge referral and treatment by modified intention to treat (mITT).
|
24 months
|
|
HCV relapse rate
기간: 24 months
|
To compare the HCV viral relapse rate in both arms (re-appearance of HCV RNA in those undetectable at end of treatment; relapse distinguished from reinfection by sequencing of the recurrent HCV RNA and comparing to baseline).
|
24 months
|
|
HCV seroprevalence rates
기간: 12 months
|
To determine HCV seroprevalence rates among acute vs addictions patients admitted to CAMH.
|
12 months
|
|
HCV RNA positivity rates
기간: 12 months
|
To determine HCV RNA positivity rates among acute vs addictions patients admitted to CAMH.
|
12 months
|
|
CAMH staff acceptability of POC antibody and RNA testing
기간: 12 months
|
CAMH staff involved in the trial will be asked to particiapte in an acceptibility survey regarding rapid POC antibody and RNA testing on the acute units.
|
12 months
|
|
Concordance of POC HCV RNA with HCV RNA by phlebotomy
기간: 12 months
|
To determine concordance of POC HCV RNA (GeneXpert) with HCV RNA by phlebotomy (Abbott RealTime).
|
12 months
|
|
Minimum and mean times from diagnosis to treatment initiation
기간: 24 months
|
Evaluate the mean and minimum times to treatment initiation in both arms, and compare.
|
24 months
|
|
Adherence with out-patient follow-up visits
기간: 24 months.
|
Evaluate and compare out-patient follow-up visit adherence in both arms.
|
24 months.
|
|
Adherence to HCV treatment, by HCV regimen
기간: 24 months.
|
Evaluate and compare both arms for medication adherence (patient self-report and pill count), and variance by medication regimen.
|
24 months.
|
|
Adverse events while on HCV treatment
기간: 18 months.
|
To determine and compare adverse events in both arms while patients are on treatment.
|
18 months.
|
|
HCV Reinfection
기간: 24 months.
|
Reinfection rates by the end of the defined as HCV RNA detectability after prior SVR with demonstration of distinct viral sequence from baseline sample to distinguish
|
24 months.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 20-5188
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
C 형 간염에 대한 임상 시험
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology Network완전한
-
Meir Medical Center완전한디지털 스테레오 광 디스크 이미지에서 C/D 비율을 측정하는 새로운 기술 개발 | C/D 측정의 관찰자 내 재현성 | C/D 측정의 관찰자 간 가변성
-
University Hospital, Bordeaux아직 모집하지 않음
-
University Hospital, Caen완전한
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... 그리고 다른 협력자들알려지지 않은